[1] ZHANG Y, ZOU J, ZHAO X, et al. Hepatitis C virus NS5A inhibitor daclatasvir allosterically impairs NS4B-involved protein-protein interactions within the viral replicase and disrupts the replicase quaternary structure in a replicase assembly surrogate system[J]. J Gen Virol, 2019, 100(1): 69. doi: 10.1099/jgv.0.001180
[2] PAUL D, MADAN V, RAMIREZ O, et al. Glycine zipper motifs in hepatitis C virus nonstructural protein 4B are required for the establishment of viral replication organelles[J]. J Virol, 2018, 92(4): e01890.
[3] KONG L, LI S, HUANG M, et al. The roles of endoplasmic reticulum overload response induced by HCV and NS4B protein in human hepatocyte viability and virus replication[J]. PLoS One, 2015, 10(4): e123190.
[4] LI S, YE L, YU X, et al. Hepatitis C virus NS4B induces unfolded protein response and endoplasmic reticulum overload response-dependent NF-κB activation[J]. Virology, 2009, 391(2): 257. doi: 10.1016/j.virol.2009.06.039
[5] HU B, LI S, ZHANG Z, et al. HCV NS4B targets Scribble for proteasome-mediated degradation to facilitate cell transformation[J]. Tumour Biol, 2016, 37(9): 12387. doi: 10.1007/s13277-016-5100-4
[6] 张战锋, 谢在春, 庞志宇, 等. NF2基因在丙肝病毒非结构蛋白4B调节细胞周期中的作用[J]. 基础医学与临床, 2019, 39(9): 1289. doi: 10.3969/j.issn.1001-6325.2019.09.014
[7] JANSE VRH, YANG X. The Hippo pathway and cancer immunity: friend or foe?[J]. Oncoscience, 2018, 5(3/4): 49.
[8] TAHA Z, JANSE VRH, YANG X. The Hippo pathway: immunity and cancer[J]. Cancers(Basel), 2018, 10(4): 94.
[9] HONG AW, MENG Z, PLOUFFE SW, et al. Critical roles of phosphoinositides and NF2 in Hippo pathway regulation[J]. Genes Dev, 2020, 34(7/8): 511.
[10] MENG Z, MOROISHI T, GUAN KL. Mechanisms of Hippo pathway regulation[J]. Genes Dev, 2016, 30(1): 1. doi: 10.1101/gad.274027.115
[11] PETRILLI AM, FUSE MA, DONNAN MS, et al. A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2[J]. Am J Transl Res, 2014, 6(5): 471.
[12] GUAN Y, GONG Z, XIAO T, et al. Knockdown of miR-572 suppresses cell proliferation and promotes apoptosis in renal cell carcinoma cells by targeting the NF2/Hippo signaling pathway[J]. Int J Clin Exp Pathol, 2018, 11(12): 5705.
[13] MIA MM, CHELAKKOT-GOVINDALAYATHIL AL, SINGH MK. Targeting NF2-Hippo/Yap signaling pathway for cardioprotection after ischemia/reperfusion injury[J]. Ann Transl Med, 2016, 4(24): 545. doi: 10.21037/atm.2016.11.85
[14] PETRILLI AM, GARCIA J, BOTT M, et al. Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells[J]. Oncotarget, 2017, 8(19): 31666. doi: 10.18632/oncotarget.15912
[15] BELTRAMI S, KIM R, GORDON J. Neurofibromatosis type 2 protein, NF2: an uncoventional cell cycle regulator[J]. Anticancer Res, 2013, 33(1): 1.